(NASDAQ: AUTL) Autolus Therapeutics's forecast annual revenue growth rate of 53.92% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Autolus Therapeutics's revenue in 2026 is $92,624,000.On average, 13 Wall Street analysts forecast AUTL's revenue for 2026 to be $35,388,073,307, with the lowest AUTL revenue forecast at $31,744,400,596, and the highest AUTL revenue forecast at $41,081,145,569. On average, 13 Wall Street analysts forecast AUTL's revenue for 2027 to be $57,521,588,470, with the lowest AUTL revenue forecast at $39,124,900,542, and the highest AUTL revenue forecast at $77,411,410,358.
In 2028, AUTL is forecast to generate $92,560,997,697 in revenue, with the lowest revenue forecast at $52,919,754,930 and the highest revenue forecast at $123,131,651,277.